526 related articles for article (PubMed ID: 10152353)
21. America's pharmaceutical research companies: keeping the cost of health care down. Pharmaceutical Manufacturers Association.
Hawaii Med J; 1992 Jan; 51(1):15-16, 19. PubMed ID: 1740387
[No Abstract] [Full Text] [Related]
22. Price controls for drugs.
Rubin PH
J Med Assoc Ga; 1995 Mar; 84(3):135-6. PubMed ID: 7738447
[No Abstract] [Full Text] [Related]
23. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
Seay M
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
[No Abstract] [Full Text] [Related]
24. Pharmaceutical policy in China.
Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
[TBL] [Abstract][Full Text] [Related]
25. Prescription drug pricing: the consumer perspective.
Searing A
N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
[No Abstract] [Full Text] [Related]
26. The perfect mix for your portfolio.
Simons J
Fortune; 2003 Dec; 148(13):134-8. PubMed ID: 14712541
[No Abstract] [Full Text] [Related]
27. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
28. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
Chodock R; Yolkut D; Connolly DR
Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
[TBL] [Abstract][Full Text] [Related]
29. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
Tan SY
Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
[No Abstract] [Full Text] [Related]
30. Precipitating factors for pharmaceutical firms.
McCarthy R
State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
[No Abstract] [Full Text] [Related]
31. Doubts emerge about drug industry mergers.
Bus Health; 1994 Nov; 12(11):53-4, 56, 61. PubMed ID: 10138536
[No Abstract] [Full Text] [Related]
32. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
33. Price controls in the pharmaceutical industry could hurt medical education.
Hull AR
Nephrol News Issues; 1993 Jun; 7(6):46-7. PubMed ID: 8133929
[No Abstract] [Full Text] [Related]
34. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
Ben-Asher D; Juris M
J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
[No Abstract] [Full Text] [Related]
35. Israel's National Health Insurance Law: expectations and concerns.
Michaeli D
Health Care Manag; 1995 Oct; 2(1):175-82. PubMed ID: 10165631
[TBL] [Abstract][Full Text] [Related]
36. Why drugs cost so much.
Noonan D
Newsweek; 2000 Sep; 136(13):22-30. PubMed ID: 11183315
[No Abstract] [Full Text] [Related]
37. The pharmaceutical industry--prices and progress.
Scherer FM
N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
[No Abstract] [Full Text] [Related]
38. Congress advances on health care reform: one step at a time.
Shultz PT; Greenman JF
Employee Relat Law J; 1996; 22(3):89-106. PubMed ID: 10163213
[TBL] [Abstract][Full Text] [Related]
39. Medicare reform's impact on long-term care.
Stefanacci RG
J Am Med Dir Assoc; 2004; 5(6):418-21. PubMed ID: 15530184
[No Abstract] [Full Text] [Related]
40. An Rx for reform: a Medicare prescription drug benefit.
Rak J
Health Matrix Clevel; 2002; 12(2):449-505. PubMed ID: 12430363
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
